This session has been fully organised and funded by Bayer and contains promotional content. Adverse event reporting and prescribing information is available at the end of the presentation. 

This presentation will provide an overview from a pharmacist’s perspective of the practicalities of managing patients with venous thromboembolism (VTE), in line with current national guidelines. With a focus on anticoagulation in VTE, the clinical evidence for the use of DOACs for the management of acute VTE and prevention of VTE recurrence will be examined along with the considerations surrounding extended anticoagulation in at-risk patients and the management of cancer-associated thrombosis (CAT).

RP-XAR-GB-4123, March 2022